OxTalks will soon move to the new Halo platform and will become 'Oxford Events.' There will be a need for an OxTalks freeze. This was previously planned for Friday 14th November – a new date will be shared as soon as it is available (full details will be available on the Staff Gateway).
In the meantime, the OxTalks site will remain active and events will continue to be published.
If staff have any questions about the Oxford Events launch, please contact halo@digital.ox.ac.uk
Two vaccines are now approved for use against Plasmodium falciparum malaria in young African children; these can prevent liver infection. However, if a single parasite slips through the net, blood-stage infection is established causing clinical disease. An effective blood-stage vaccine (or second line of defence), however, has proved elusive. We have developed vaccines targeting the P. falciparum RH5 antigen, which mediates a conserved and essential invasion pathway into the human red blood cell. Rational vaccine design has built on our understanding of how vaccine-induced anti-RH5 human antibodies inhibit parasite growth. This talk will describe our work to understand human anti-malarial antibodies and present data from Phase 1/2 clinical trials of RH5-based blood-stage vaccines undertaken in the UK and across Africa.
